Board of Directors
Erich Mohr, Ph.D., ICD.D.
Chairman & Chief Executive Officer
Founder of MedGenesis Therapeutix Inc.
Dr. Mohr is the Chairman and CEO of MedGenesis Therapeutix Inc. which he founded in 2006. Dr. Mohr, a Professor of Medicine and Psychology at the University of Ottawa until 1997 has over 30 years of experience in experimental therapeutics of CNS disorders. He is credited with over 150 publications, book chapters and abstracts and has edited the Handbook of Clinical Trials: The neurobehavioral approach. Dr. Mohr has chaired and/or served on several regulatory advisory panels for the approval of new products for the treatment of neurodegenerative disease and is the former Chairman and Chief Executive Officer of CroMedica Global Inc. (which merged with PRA International in 2002 to form one of the world's leading contract research organizations) and is the current or past Chairman of several biotechnology companies. His most recent executive position was with PRA International as Chief Scientific Officer. He also served more recently as Chair of the Board of Governors of the University of Victoria and is a current board member of several biotechnology companies. Over the course of his career, Dr. Mohr has overseen and/or participated in more than a dozen clinical development programs resulting in a number of approved drugs.
Former President, CroMedica Global Inc.
Ken Newport is an entrepreneur and life sciences business executive. As a graduate of the University of Waterloo and a Chartered Accountant, Mr. Newport had early success in the financial services industry and served as a partner in a Chartered Accounting firm. His focus changed to life sciences in the mid-nineties with the formation of CroMedica Global Inc., a contract research organization. As co-founder and President he witnessed CroMedica's growth to 600 employees within six years. By the time that CroMedica merged with PRA International Inc. in 2002 CroMedica had annual revenues of over $40 million with 13 offices in 9 countries. The combined company became one of the largest contract research organizations in the world with over 17,000 employees. Mr. Newport served as a Senior Vice President and Executive Committee member until 2005. Mr. Newport was also a founding member of Global Biomedical Capital Corporation, Zelos Therapeutics Inc., Prime Trials Inc. and other life science organizations. He is now a corporate director and has earned the ICD.D designation. He serves or has served on several corporate and not for profit Boards including his role as Chairman of BioCanRx.
Principal Consultant, Cagley Johnson Consulting Inc.
Greg Johnson has more than 25 years of experience in Biotech and Clinical Research, with recognized expertise in strategic planning, project management and operations management, as well as in electronic data capture and the implementation and use of computerized systems in a clinical research setting. Mr. Johnson is a principal with Cagley Johnson Consulting Inc. Prior to founding his consulting company, he was Chief Operating Officer then President and Chief Financial Officer for MedGenesis Therapeutix (2007-2017). Mr. Johnson previously held a number of senior roles at PRA International (1992-2007; now PRA Health Sciences) in four different countries. Mr. Johnson has an M.Sc. in Clinical Research from Liverpool John Moores University, professional certification (PMP) through the Project Management Institute and is a Fellow of the Institute of Clinical Research (FICR).